The Food and Drug Administration has threatened criminal action against Novartis for using inaccurate data in a drug application. Novartis subsidiary AveXis told the FDA that a “data-manipulation issue” led to inaccurate data in the application for Zolgensma. The drug, which was approved in May, treats spinal muscular atrophy. (CNBC)

Opioid distributors have proposed a $10 billion settlement to resolve state lawsuits. McKesson, Cardinal Health and AmerisourceBergen put forward the proposal to a group of state attorneys general who are handling negotiations for lawsuits from more than 35 states. The state officials countered with a $45 billion settlement proposal. (Bloomberg)

GlaxoSmithKline has ended work on an experimental Ebola vaccine. The Sabin Vaccine Institute will take over GSK’s work, which included an experimental Ebola vaccine. GSK is refocusing its research and development on franchise drugs. (Endpoints)

Experts said the rising number of prescriptions of overdose-reversal drug naloxone could be contributing to the drop in overdose deaths. The number of naloxone prescriptions more than doubled from 2017 to last year, rising from 271,000 to 557,000. The number of overdose deaths dropped for the first time in years in 2017. (Associated Press)

Amag Pharmaceutical’s female libido drug will be priced at $899. The treatment, Vyleesi, is an injectible drug indicated to treat hypoactive sexual desire disorder in postmenopausal women. Approved in June, it will be available next month. (Reuters)